Articles with public access mandates - Isabelle Ray-CoquardLearn more
Not available anywhere: 11
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised …
O Mir, C Cropet, M Toulmonde, A Le Cesne, M Molimard, E Bompas, ...
The Lancet Oncology 17 (5), 632-641, 2016
Mandates: National Institute of Health and Medical Research, France, Swiss Cancer League
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
S Pignata, D Lorusso, F Joly, C Gallo, N Colombo, C Sessa, A Bamias, ...
The Lancet Oncology 22 (2), 267-276, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
Low-grade serous ovarian cancer: state of the science
B Slomovitz, C Gourley, MS Carey, A Malpica, IM Shih, D Huntsman, ...
Gynecologic oncology 156 (3), 715-725, 2020
Mandates: Cancer Research UK
DICER1 and FOXL2 mutations in ovarian sex cord–stromal tumours: a GINECO Group study
T Goulvent, I Ray‐Coquard, S Borel, V Haddad, ...
Histopathology 68 (2), 279-285, 2016
Mandates: Swiss Cancer League
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration
M Small, I Treilleux, C Couillault, D Pissaloux, G Picard, S Paindavoine, ...
Acta neuropathologica 135, 569-579, 2018
Mandates: Swiss Cancer League
Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study
M Toulmonde, M Brahmi, A Giraud, C Chakiba, A Bessede, M Kind, ...
Clinical Cancer Research 28 (9), 1765-1772, 2022
Mandates: National Institute of Health and Medical Research, France, Agence Nationale …
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
EM Swisher, RS Kristeleit, AM Oza, AV Tinker, I Ray-Coquard, A Oaknin, ...
Gynecologic oncology 163 (3), 490-497, 2021
Mandates: US Department of Defense, National Institute for Health Research, UK
Endometrial cancer (primer)
M Vicky, H MacKay, I Ray-Coquard, DA Levine, SN Westin, A Daisuke, ...
Nature Reviews: Disease Primers 7 (1), 2021
Mandates: US National Institutes of Health
New clinical research strategies for rare gynecologic malignancies
I Ray-Coquard, E Pujade-Lauraine, JA Ledermann
Current Opinion in Obstetrics and Gynecology 27 (1), 53-57, 2015
Mandates: US National Institutes of Health
Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS
G Chvetzoff, C Bouleuc, A Lardy-Cléaud, P Saltel, V Dieras, M Morelle, ...
Supportive Care in Cancer 31 (1), 82, 2023
Mandates: Swiss Cancer League
Fifteen important questions for oncology to be addressed from 2015
JY Blay, O Tredan, I Ray-Coquard, M Rivoire, P Mehlen, A Puisieux, ...
Bulletin du Cancer 102 (6), S22-S26, 2015
Mandates: Swiss Cancer League
Available somewhere: 136
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ...
New England Journal of Medicine 381 (25), 2416-2428, 2019
Mandates: German Research Foundation
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ...
Annals of oncology 30 (5), 672-705, 2019
Mandates: US Department of Defense
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ...
The lancet oncology 18 (1), 75-87, 2017
Mandates: US Department of Defense, Cancer Research UK, UK Medical Research Council, V …
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
I Ray-Coquard, C Cropet, M Van Glabbeke, C Sebban, A Le Cesne, ...
Cancer research 69 (13), 5383-5391, 2009
Mandates: US National Institutes of Health
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
RE Miller, A Leary, CL Scott, V Serra, CJ Lord, D Bowtell, DK Chang, ...
Annals of Oncology 31 (12), 1606-1622, 2020
Mandates: Cancer Research UK, Wellcome Trust, Dutch Cancer Society
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ...
Cancer discovery 9 (2), 210-219, 2019
Mandates: US Department of Defense, Cancer Research UK, UK Medical Research Council, V …
Endometrial cancer
V Makker, H MacKay, I Ray-Coquard, DA Levine, SN Westin, D Aoki, ...
Nature reviews Disease primers 7 (1), 88, 2021
Mandates: US National Institutes of Health
Improved survival using specialized multidisciplinary board in sarcoma patients
JY Blay, P Soibinet, N Penel, E Bompas, F Duffaud, E Stoeckle, O Mir, ...
Annals of Oncology 28 (11), 2852-2859, 2017
Mandates: US National Institutes of Health, European Commission
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre …
WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ...
The lancet oncology 18 (8), 1089-1103, 2017
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program